Mitochondrial Carrier Ata 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitochondrial Carrier ATA-1 (also known as ORNT1, SLC25A15) is a mitochondrial carrier protein that transports amino acids across the inner mitochondrial membrane. It plays a crucial role in the urea cycle and mitochondrial metabolism. Mutations in the SLC25A15 gene cause the rare metabolic disorder Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome, characterized by neurological symptoms.
Structure
...
Mitochondrial Carrier ATA-1 Protein
Introduction
Mitochondrial Carrier Ata 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitochondrial Carrier ATA-1 (also known as ORNT1, SLC25A15) is a mitochondrial carrier protein that transports amino acids across the inner mitochondrial membrane. It plays a crucial role in the urea cycle and mitochondrial metabolism. Mutations in the SLC25A15 gene cause the rare metabolic disorder Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome, characterized by neurological symptoms.
Structure
Mitochondrial carriers share a common structural fold:
Three Mitochondrial Carrier Domains: Each ~100 amino acids
Six Transmembrane α-Helices: Form the transport channel
Three Internal Repeats: Symmetric three-fold symmetry
Matrix-facing and Intermembrane Space-facing Gates: Regulate substrate transport
Key structural features:
PXD motif: Proline-X-Aspartate in each repeat
Carrier-specific substrate-binding site
Salt bridge network: For substrate recognition
Normal Function
Transport Activities
Ornithine Transport: Exchanges ornithine with citrulline across the inner membrane
Lysine Transport: Low affinity for basic amino acids
Histidine Transport: Minor substrate
Physiological Roles
Urea Cycle: Links mitochondrial and cytosolic portions
Treatment: Dietary protein restriction, ammonia scavengers
General Neurodegeneration
Mitochondrial Dysfunction: Energy metabolism defects
Ammonia Toxicity: In HHH syndrome, hyperammonemia damages [neurons](/entities/neurons)
Oxidative Stress: Impaired mitochondrial function
Potential Links
Altered Ornithine Metabolism: May affect polyamine synthesis
Mitochondrial Energy Defects: Common in neurodegeneration
Therapeutic Implications
Drug Development
Enzyme Replacement: Not applicable (transport protein)
Gene Therapy: Potential for HHH syndrome
Small Molecule Modulators: Experimental
Clinical Management
HHH Syndrome Treatment:
Protein restriction
Ammonia scavengers (sodium phenylbutyrate)
Arginine supplementation
Ornithine supplementation
Research Directions
Understanding substrate specificity
Developing treatments for HHH syndrome
Mitochondrial carrier modulation for neurodegeneration
Biomarkers for mitochondrial transport function
Background
The study of Mitochondrial Carrier Ata 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Disease Mechanisms
HHH Syndrome Pathogenesis
The HHH syndrome (Hyperornithinemia-Hyperammonemia-Homocitrullinuria) results from impaired ornithine transport across the mitochondrial membrane. This leads to: